WILLIAM CHANDLER CUSHMAN, M.D., B.A.

Professor, Preventive Medicine, Medicine, Medicine, Physiology

Office: 5159 VETERANS AFFAIRS MEDICAL CENTER
1030 JEFFERSON AVENUE
MEMPHIS TN 381040000
Tel: (901) 577-7357
wcushman@uthsc.edu

Education

  • M.D., University of Mississippi School of Medicine, Jackson, Mississippi, Medicine
  • B.A., University of Mississippi at Oxford, MS, Chemistry and Biology

Publications

  1. Cushman, WC, Bakris, GL, White, WB, Weber, MA, Sica, D, Roberts, A, Lloyd, E, Kupfer, S. A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension. J Hypertens, 2018.
  2. Spivey, CA, Wang, J, Qiao, Y, Shih, YT, Wan, JY, Kuhle, J, Dagogo-Jack, S, Cushman, WC, Chisholm-Burns, M. Racial and Ethnic Disparities in Meeting MTM Eligibility Criteria Based on Star Ratings Compared with the Medicare Modernization Act. J Manag Care Spec Pharm, 24 (2), 97-107, 2018.
  3. Gerstein, HC, Colhoun, HM, Dagenais, GR, Diaz, R, Lakshmanan, M, Pais, P, Probstfield, J, Riddle, MC, Rydén, L, Xavier, D, Atisso, CM, Avezum, A, Basile, J, Chung, N, Conget, I, Cushman, WC, Franek, E, Hancu, N, Hanefeld, M, Holt, S, Jansky, P, Keltai, M, Lanas, F, Leiter, LA, Lopez-Jaramillo, P, Cardona-Munoz, EG, Pirags, V, Pogosova, N, Raubenheimer, PJ, Shaw, J, Sheu, WH, Temelkova-Kurktschiev, T, ,. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab, 20 (1), 42-49, 2018.
  4. Barzilay, JI, Davis, BR, Pressel, SL, Ghosh, A, Rahman, M, Einhorn, PT, Cushman, WC, Whelton, PK, Wright, JT. The Effects of eGFR Change on CVD, Renal, and Mortality Outcomes in a Hypertensive Cohort Treated With 3 Different Antihypertensive Medications. Am J Hypertens, 2018.
  5. Beddhu, S, Chertow, GM, Cheung, AK, Cushman, WC, Rahman, M, Greene, T, Wei, G, Campbell, RC, Conroy, M, Freedman, BI, Haley, W, Horwitz, E, Kitzman, D, Lash, J, Papademetriou, V, Pisoni, R, Riessen, E, Rosendorff, C, Watnick, SG, Whittle, J, Whelton, PK, ,. Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control. Circulation, 137 (2), 134-143, 2018.
  6. Headley, CM, Wall, BM, Cushman, WC. A Blood Pressure You Can Believe In. Nephrol Nurs J, 44 (1), 57-71, 2017.
  7. Hwang, YC, Morrow, DA, Cannon, CP, Liu, Y, Bergenstal, R, Heller, S, Mehta, C, Cushman, W, Bakris, GL, Zannad, F, White, WB. High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial. Diabetes Obes Metab, 2017.
  8. Cheung, AK, Rahman, M, Reboussin, DM, Craven, TE, Greene, T, Kimmel, PL, Cushman, WC, Hawfield, AT, Johnson, KC, Lewis, CE, Oparil, S, Rocco, MV, Sink, KM, Whelton, PK, Wright, JT, Basile, J, Beddhu, S, Bhatt, U, Chang, TI, Chertow, GM, Chonchol, M, Freedman, BI, Haley, W, Ix, JH, Katz, LA, Killeen, AA, Papademetriou, V, Ricardo, AC, Servilla, K, Wall, B, Wolfgram, D, Yee, J, ,. Effects of Intensive BP Control in CKD. J Am Soc Nephrol, 28 (9), 2812-2823, 2017.
  9. Neutel, JM, Cushman, WC, Lloyd, E, Barger, B, Handley, A. Comparison of long-term safety of fixed-dose combinations azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide. J Clin Hypertens (Greenwich), 19 (9), 874-883, 2017.
  10. Soliman, EZ, Ambrosius, WT, Cushman, WC, Zhang, ZM, Bates, JT, Neyra, JA, Carson, TY, Tamariz, L, Ghazi, L, Cho, ME, Shapiro, BP, He, J, Fine, LJ, Lewis, CE, ,. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial). Circulation, 136 (5), 440-450, 2017.
  11. Bress, AP, King, JB, Kreider, KE, Beddhu, S, Simmons, DL, Cheung, AK, Zhang, Y, Doumas, M, Nord, J, Sweeney, ME, Taylor, AA, Herring, C, Kostis, WJ, Powell, J, Rastogi, A, Roumie, CL, Wiggers, A, Williams, JS, Yunis, R, Zias, A, Evans, GW, Greene, T, Rocco, MV, Cushman, WC, Reboussin, DM, Feinglos, MN, Papademetriou, V, ,. Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial. Diabetes Care, 2017.
  12. Cavender, MA, White, WB, Jarolim, P, Bakris, GL, Cushman, WC, Kupfer, S, Gao, Q, Mehta, CR, Zannad, F, Cannon, CP, Morrow, DA. Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care). Circulation, 135 (20), 1911-1921, 2017.
  13. Rossignol, P, Agarwal, R, Canaud, B, Charney, A, Chatellier, G, Craig, JC, Cushman, WC, Gansevoort, RT, Fellström, B, Garza, D, Guzman, N, Holtkamp, FA, London, GM, Massy, ZA, Mebazaa, A, Mol, PGM, Pfeffer, MA, Rosenberg, Y, Ruilope, LM, Seltzer, J, Shah, AM, Shah, S, Singh, B, Stefánsson, BV, Stockbridge, N, Stough, WG, Thygesen, K, Walsh, M, Wanner, C, Warnock, DG, Wilcox, CS, Wittes, J, Pitt, B, Thompson, A, Zannad, F. Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints. Eur Heart J, 2017.
  14. Upadhya, B, Rocco, M, Lewis, CE, Oparil, S, Lovato, LC, Cushman, WC, Bates, JT, Bello, NA, Aurigemma, G, Fine, LJ, Johnson, KC, Rodriguez, CJ, Raj, DS, Rastogi, A, Tamariz, L, Wiggers, A, Kitzman, DW, ,. Effect of Intensive Blood Pressure Treatment on Heart Failure Events in the Systolic Blood Pressure Reduction Intervention Trial. Circ Heart Fail, 10 (4), 2017.
  15. Haywood, LJ, Davis, BR, Piller, LB, Cushman, WC, Cutler, JA, Ford, CE, Simpson, LM, Ghosh, A, Soliman, EZ, Wright, JT, ,. Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT. J Natl Med Assoc, 109 (3), 172-181, 2016.
  16. Espeland, MA, Probstfield, J, Hire, D, Redmon, JB, Evans, GW, Coday, M, Lewis, CE, Johnson, KC, Wilmoth, S, Bahnson, J, Dulin, MF, Green, JB, Knowler, WC, Kitabchi, A, Murillo, AL, Osei, K, Rehman, SU, Cushman, WC, , , ,. Systolic Blood Pressure Control Among Individuals With Type 2 Diabetes: A Comparative Effectiveness Analysis of Three Interventions. Am J Hypertens, 28 (8), 995-1009, 2015.
  17. Muntner, P, Whittle, J, Lynch, AI, Colantonio, LD, Simpson, LM, Einhorn, PT, Levitan, EB, Whelton, PK, Cushman, WC, Louis, GT, Davis, BR, Oparil, S. Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study. Ann Intern Med, 2015.
  18. Zannad, F, Cannon, CP, Cushman, WC, Bakris, GL, Menon, V, Perez, AT, Fleck, PR, Mehta, CR, Kupfer, S, Wilson, C, Lam, H, White, WB, ,. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet, 385 (9982), 2067-76, 2015.
  19. Einhorn, PT, Whelton, PK, Davis, BR, Wright, JT, Cushman, WC, Zieman, SJ. Real-world evidence supports optimally dosed thiazide-type diuretics as preferred in treatment regimens of older adults with hypertension. J Am Geriatr Soc, 63 (5), 1045-7, 2015.
  20. Papademetriou, V, Lovato, L, Doumas, M, Nylen, E, Mottl, A, Cohen, RM, Applegate, WB, Puntakee, Z, Yale, JF, Cushman, WC, ,. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney Int, 87 (3), 649-59, 2015.
  21. Yamal, JM, Oparil, S, Davis, BR, Alderman, MH, Calhoun, DA, Cushman, WC, Fendley, HF, Franklin, SS, Habib, GB, Pressel, SL, Probstfield, JL, Sastrasinh, S, ,. Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT. J Am Soc Hypertens, 8 (11), 808-19, 2014.
  22. Muntner, P, Davis, BR, Cushman, WC, Bangalore, S, Calhoun, DA, Pressel, SL, Black, HR, Kostis, JB, Probstfield, JL, Whelton, PK, Rahman, M, ,. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension, 64 (5), 1012-21, 2014.
  23. Gosmanova, EO, Lu, JL, Streja, E, Cushman, WC, Kalantar-Zadeh, K, Kovesdy, CP. Association of medical treatment nonadherence with all-cause mortality in newly treated hypertensive US veterans. Hypertension, 64 (5), 951-7, 2014.
  24. Ambrosius, WT, Sink, KM, Foy, CG, Berlowitz, DR, Cheung, AK, Cushman, WC, Fine, LJ, Goff, DC, Johnson, KC, Killeen, AA, Lewis, CE, Oparil, S, Reboussin, DM, Rocco, MV, Snyder, JK, Williamson, JD, Wright, JT, Whelton, PK, ,. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials, 11 (5), 532-46, 2014.
  25. Wang, J, Qiao, Y, Shih, YC, Jamison, JJ, Spivey, CA, Li, L, Wan, JY, White-Means, SI, Dagogo-Jack, S, Cushman, WC, Chisholm-Burns, M. Effects of medicare part d on disparity implications of medication therapy management eligibility criteria. Am Health Drug Benefits, 7 (6), 346-58, 2014.
  26. Wang, J, Qiao, Y, Tina Shih, YC, Spivey, CA, Dagogo-Jack, S, Wan, JY, White-Means, SI, Cushman, WC, Chisholm-Burns, MA. Potential effects of racial and ethnic disparities in meeting Medicare medication therapy management eligibility criteria. J Pharm Health Serv Res, 5 (2), 109-118, 2014.
  27. Margolis, KL, O'Connor, PJ, Morgan, TM, Buse, JB, Cohen, RM, Cushman, WC, Cutler, JA, Evans, GW, Gerstein, HC, Grimm, RH, Lipkin, EW, Narayan, KM, Riddle, MC, Sood, A, Goff, DC. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care, 37 (6), 1721-8, 2014.
  28. Vemulapalli, S, Ard, J, Bakris, GL, Bhatt, DL, Brown, AS, Cushman, WC, Ferdinand, KC, Flack, JM, Fleg, JL, Katzen, BT, Kostis, JB, Oparil, S, Patel, CB, Pepine, CJ, Piña, IL, Rocha-Singh, KJ, Townsend, RR, Peterson, ED, Califf, RM, Patel, MR. Proceedings from Duke resistant hypertension think tank. Am Heart J, 167 (6), 775-88.e1, 2014.
  29. Oparil, S, Cushman, WC, Lederle, FA. Chlorthalidone versus hydrochlorothiazide in hypertension treatment: do we have the evidence to decide. Am J Kidney Dis, 63 (3), 387-9, 2014.
  30. James, PA, Oparil, S, Carter, BL, Cushman, WC, Dennison-Himmelfarb, C, Handler, J, Lackland, DT, LeFevre, ML, MacKenzie, TD, Ogedegbe, O, Smith, SC, Svetkey, LP, Taler, SJ, Townsend, RR, Wright, JT, Narva, AS, Ortiz, E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA, 311 (5), 507-20, 2014.
  31. Miller, ME, Williamson, JD, Gerstein, HC, Byington, RP, Cushman, WC, Ginsberg, HN, Ambrosius, WT, Lovato, L, Applegate, WB, ,. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care, 37 (3), 634-43, 2013.
  32. White, WB, Cannon, CP, Heller, SR, Nissen, SE, Bergenstal, RM, Bakris, GL, Perez, AT, Fleck, PR, Mehta, CR, Kupfer, S, Wilson, C, Cushman, WC, Zannad, F, ,. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med, 369 (14), 1327-35, 2013.
  33. Kovesdy, CP, Bleyer, AJ, Molnar, MZ, Ma, JZ, Sim, JJ, Cushman, WC, Quarles, LD, Kalantar-Zadeh, K. Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study. Ann Intern Med, 159 (4), 233-42, 2013.
  34. Einhorn, PT, Cushman, WC, Whelton, PK, ,. Chlorthalidone versus hydrochlorothiazide. Ann Intern Med, 158 (12), 922-3, 2013.
  35. Bakris, GL, Sica, D, White, WB, Cushman, WC, Weber, MA, Handley, A, Song, E, Kupfer, S. Antihypertensive Efficacy of Hydrochlorothiazide vs Chlorthalidone Combined with Azilsartan Medoxomil. Am J Med, 125 (12), 1229.e1-1229.e10, 2012.
  36. Wang, J, Qiao, Y, Tina Shih, YC, Wan, JY, White-Means, SI, Dagogo-Jack, S, Cushman, WC. Potential health implications of racial and ethnic disparities in meeting MTM eligibility criteria. Res Social Adm Pharm, 10 (1), 106-25, 2012.
  37. Proschan, M, Ford, CE, Cutler, JA, Graumlich, JF, Pavlik, V, Cushman, WC, Davis, BR, Alderman, MH, Gordon, D, Furberg, CD, Franklin, SS, Blumenthal, SS, Castaldo, RS, Preston, RA, ,. How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure. Stat Med, 2012.
  38. Cushman, WC. Getting to goal: how thiazide-type diuretics, following the guidelines, and improving patient adherence can help. Module 2: rethinking the role of thiazide-type diuretics in the management of hypertension: which diuretic is best. J Fam Pract, 61 (8 Suppl), S15-9, 2012.
  39. Ferrannini, E, Cushman, WC. Diabetes and hypertension: the bad companions. Lancet, 380 (9841), 601-10, 2012.
  40. Cushman, WC, Bakris, GL, White, WB, Weber, MA, Sica, D, Roberts, A, Lloyd, E, Kupfer, S. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension, 60 (2), 310-8, 2012.
  41. Barzilay, JI, Howard, AG, Evans, GW, Fleg, JL, Cohen, RM, Booth, GL, Kimel, AR, Pedley, CF, Cushman, WC. Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. Diabetes Care, 35 (7), 1401-5, 2012.
  42. Krousel-Wood, M, Muntner, P, Carson, A, Anderson, AH, Delaune, E, Cushman, WC, Cutler, JA, Piller, LB, Goforth, GA, Whelton, PK. Hypertension control among newly treated patients before and after publication of the main ALLHAT results and JNC 7 guidelines. J Clin Hypertens (Greenwich), 14 (5), 277-83, 2012.
  43. Sica, D, Bakris, GL, White, WB, Weber, MA, Cushman, WC, Huang, P, Roberts, A, Kupfer, S. Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. J Clin Hypertens (Greenwich), 14 (5), 284-92, 2012.
  44. Zannad, F, Stough, WG, Pocock, SJ, Sleight, P, Cushman, WC, Cleland, JG, McMurray, JJ, Lonn, E, Geller, NL, Wedel, H, Abadie, E, Alonso-Garcia, A, Pitt, B. Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements. Eur Heart J, 33 (9), 1049-57, 2012.
  45. Alderman, MH, Piller, LB, Ford, CE, Probstfield, JL, Oparil, S, Cushman, WC, Einhorn, PT, Franklin, SS, Papademetriou, V, Ong, ST, Eckfeldt, JH, Furberg, CD, Calhoun, DA, Davis, BR, ,. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension, 59 (5), 926-33, 2012.
  46. Walker, R, Hunt, YM, Olivier, J, Grothe, KB, Dubbert, PM, Burke, RS, Cushman, WC. Descriptive characteristics and cluster analysis of male veteran hazardous drinkers in an alcohol moderation intervention. Am J Addict, 21 (4), 335-42, 2012.
  47. Weintraub, HS, Duprez, DA, Cushman, WC, Zappe, DH, Purkayastha, D, Samuel, R, Izzo, JL. Antihypertensive response to thiazide diuretic or angiotensin receptor blocker in elderly hypertensives is not influenced by pretreatment plasma renin activity. Cardiovasc Drugs Ther, 26 (2), 145-55, 2012.
  48. Barzilay, JI, Davis, BR, Pressel, SL, Cutler, JA, Einhorn, PT, Black, HR, Cushman, WC, Ford, CE, Margolis, KL, Moloo, J, Oparil, S, Piller, LB, Simmons, DL, Sweeney, ME, Whelton, PK, Wong, ND, Wright, JT, ,. Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study. Circ Cardiovasc Qual Outcomes, 5 (2), 153-62, 2012.
  49. Ismail-Beigi, F, Craven, TE, O'Connor, PJ, Karl, D, Calles-Escandon, J, Hramiak, I, Genuth, S, Cushman, WC, Gerstein, HC, Probstfield, JL, Katz, L, Schubart, U, ,. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney Int, 81 (6), 586-94, 2012.
  50. Cushman, WC, Duprez, DA, Weintraub, HS, Purkayastha, D, Zappe, D, Samuel, R, Izzo, JL. Home and clinic blood pressure responses in elderly individuals with systolic hypertension. J Am Soc Hypertens, 6 (3), 210-8, 2012.
  51. Cushman, WC, Davis, BR, Pressel, SL, Cutler, JA, Einhorn, PT, Ford, CE, Oparil, S, Probstfield, JL, Whelton, PK, Wright, JT, Alderman, MH, Basile, JN, Black, HR, Grimm, RH, Hamilton, BP, Haywood, LJ, Ong, ST, Piller, LB, Simpson, LM, Stanford, C, Weiss, RJ, ,. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Clin Hypertens (Greenwich), 14 (1), 20-31, 2012.
  52. Izzo, JL, Weintraub, HS, Duprez, DA, Purkayastha, D, Zappe, D, Samuel, R, Cushman, WC. Treating systolic hypertension in the very elderly with valsartan-hydrochlorothiazide vs. either monotherapy: ValVET primary results. J Clin Hypertens (Greenwich), 13 (10), 722-30, 2011.
  53. Piller, LB, Baraniuk, S, Simpson, LM, Cushman, WC, Massie, BM, Einhorn, PT, Oparil, S, Ford, CE, Graumlich, JF, Dart, RA, Parish, DC, Retta, TM, Cuyjet, AB, Jafri, SZ, Furberg, CD, Saklayen, MG, Thadani, U, Probstfield, JL, Davis, BR, ,. Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation, 124 (17), 1811-8, 2011.
  54. Duprez, DA, Weintraub, HS, Cushman, WC, Purkayastha, D, Zappe, D, Samuel, R, Izzo, JL. Effect of valsartan, hydrochlorothiazide, and their combination on 24-h ambulatory blood pressure response in elderly patients with systolic hypertension: a ValVET substudy. Blood Press Monit, 16 (4), 186-96, 2011.
  55. Wright, JT, Agodoa, LY, Appel, L, Cushman, WC, Taylor, AL, Obegdegbe, GG, Osei, K, Reed, J. New recommendations for treating hypertension in black patients: evidence and/or consensus. Hypertension, 56 (5), 801-3, 2010.
  56. Wang, J, Mullins, CD, Brown, LM, Shih, YC, Dagogo-Jack, S, Hong, SH, Cushman, WC. Disparity implications of Medicare eligibility criteria for medication therapy management services. Health Serv Res, 45 (4), 1061-82, 2010.
  57. Ismail-Beigi, F, Craven, T, Banerji, MA, Basile, J, Calles, J, Cohen, RM, Cuddihy, R, Cushman, WC, Genuth, S, Grimm, RH, Hamilton, BP, Hoogwerf, B, Karl, D, Katz, L, Krikorian, A, O'Connor, P, Pop-Busui, R, Schubart, U, Simmons, D, Taylor, H, Thomas, A, Weiss, D, Hramiak, I, ,. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet, 376 (9739), 419-30, 2010.
  58. Bailey, JE, Wan, JY, Tang, J, Ghani, MA, Cushman, WC. Antihypertensive medication adherence, ambulatory visits, and risk of stroke and death. J Gen Intern Med, 25 (6), 495-503, 2010.
  59. Stafford, RS, Bartholomew, LK, Cushman, WC, Cutler, JA, Davis, BR, Dawson, G, Einhorn, PT, Furberg, CD, Piller, LB, Pressel, SL, Whelton, PK, ,. Impact of the ALLHAT/JNC7 Dissemination Project on thiazide-type diuretic use. Arch Intern Med, 170 (10), 851-8, 2010.
  60. , , Ginsberg, HN, Elam, MB, Lovato, LC, Crouse, JR, Leiter, LA, Linz, P, Friedewald, WT, Buse, JB, Gerstein, HC, Probstfield, J, Grimm, RH, Ismail-Beigi, F, Bigger, JT, Goff, DC, Cushman, WC, Simons-Morton, DG, Byington, RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med, 362 (17), 1563-74, 2010.
  61. ACCORD Study Group; ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC Jr, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ.. Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes.. N Engl J Med, 363 (3), 233-244, 2010.
  62. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F.. Effects of intensive blood-pressure control in type 2 diabetes mellitus.. N Engl J Med, 362 (17), 1575-85, 2010.
  63. Mount, DL, Feeney, P, Fabricatore, AN, Coday, M, Bahnson, J, Byington, R, Phelan, S, Wilmoth, S, Knowler, WC, Hramiak, I, Osei, K, Sweeney, ME, Espeland, MA, ,. Constructing common cohorts from trials with overlapping eligibility criteria: implications for comparing effect sizes between trials. Clin Trials, 6 (5), 416-29, 2009.
  64. Bartholomew, LK, Cushman, WC, Cutler, JA, Davis, BR, Dawson, G, Einhorn, PT, Graumlich, JF, Piller, LB, Pressel, S, Roccella, EJ, Simpson, L, Whelton, PK, Williard, A, Allhat Collaborative Research Group,. Getting clinical trial results into practice: design, implementation, and process evaluation of the ALLHAT Dissemination Project. Clin Trials, 6 (4), 329-43, 2009.
  65. Wright, JT, Probstfield, JL, Cushman, WC, Pressel, SL, Cutler, JA, Davis, BR, Einhorn, PT, Rahman, M, Whelton, PK, Ford, CE, Haywood, LJ, Margolis, KL, Oparil, S, Black, HR, Alderman, MH, ,. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med, 169 (9), 832-42, 2009.
  66. Chrysant, SG, Neutel, JM, Ferdinand, KC, ,. Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial. J Natl Med Assoc, 101 (4), 300-7, 2009.
  67. , , Buse, JB, Bigger, JT, Byington, RP, Cooper, LS, Cushman, WC, Friedewald, WT, Genuth, S, Gerstein, HC, Ginsberg, HN, Goff, DC, Grimm, RH, Margolis, KL, Probstfield, JL, Simons-Morton, DG, Sullivan, MD. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol, 99 (12A), 21i-33i, 2007.